Vaginal, Oral and Systemic Inflammation in Preterm Birth
| Tracking Information | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| First Received Date ICMJE | June 7, 2010 | ||||||||
| Last Updated Date | December 27, 2012 | ||||||||
| Start Date ICMJE | November 2011 | ||||||||
| Estimated Primary Completion Date | December 2013 (final data collection date for primary outcome measure) | ||||||||
| Current Primary Outcome Measures ICMJE |
Difference in systemic and local parameters of infection between patients at risk and controls [ Time Frame: The study period is meant to be 2 years. Measures will be carried out during pregnancy, within 2 days after birth and 6 weeks post-partum. ] [ Designated as safety issue: No ] Oral, vaginal and placental infection parameters are measured during pregnancy, at birth and 6 weeks post partum. Samples are collected from blood, vaginal and placental (at birth) smears, histology, and oral smears. Measures include microbiologic culturing, gram stains, CRP, Cytokines (TNFalpha, IL-1beta, IL-6, IL-8, IL-10, PgE2). From blood samples a differential blood count, CRP, and cytokines are determined. |
||||||||
| Original Primary Outcome Measures ICMJE | Same as current | ||||||||
| Change History | Complete list of historical versions of study NCT01142752 on ClinicalTrials.gov Archive Site | ||||||||
| Current Secondary Outcome Measures ICMJE | Not Provided | ||||||||
| Original Secondary Outcome Measures ICMJE | Not Provided | ||||||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||||||
| Descriptive Information | |||||||||
| Brief Title ICMJE | Vaginal, Oral and Systemic Inflammation in Preterm Birth | ||||||||
| Official Title ICMJE | Vaginal, Oral and Systemic Inflammation in Preterm Birth | ||||||||
| Brief Summary | The prevalence of preterm birth is not decreasing in the last decades despite of improving health care. Intrauterine infections are important in the etiology of preterm birth but the interconnection of systemic inflammation and preterm birth is not clear. Mechanisms of preterm birth should be assessed as preterm birth is the major risk factor for morbidity and mortality during birth, thus being important for the individual and regarding health costs. No interventions will be carried out in this study. Hypotheses:
|
||||||||
| Detailed Description | Vaginal, oral and systemic inflammation in preterm birth
We aim to test the following hypotheses regarding associations between oral infection and PTB: I. There is a shared infectious aetiology between oral and vaginal infections (primary outcome) II. In women at risk for PTB the vaginal and oral bacterial microbiota are similar III. There are similar systemic and/or local inflammatory responses (haematogenous dissemination and bacteraemia, feto-maternal immune response) that can be induced by vaginal and/or oral infection, contributing to PTB IV. Elevated inflammatory markers are found at the onset of symptoms in pregnant women at risk for PTB and normalize after birth 3.2. Patient grouping The study design is a longitudinal, non-interventional case-control study of pregnant women including (I) a control group of women with uneventful pregnancy (II) a group of women medically considered at risk for PTB and actually delivering preterm (III) a group of women medically considered at risk for PTB but with uneventful pregnancy. Subjects will be examined at three time points (I) within 18-34 weeks of pregnancy when they get symptomatic (II) within two days after delivery and (III) 4-6 weeks post-partum. This would allow us to compare all examined parameters between and within groups over the defined time frame. Due to the medical inclusion criteria clinical medical/dental examinators cannot be blinded. At the first examination the clinicians will not know whether subjects belong to group II or group III. All laboratory processes will, however, be performed with no knowledge of group assignment. We intend to enrol a total of 180 pregnant women with a clinically perceived risk for PTB or at no/low risk based on routine clinical assessment criteria. Consecutive consenting pregnant women seeking care at, or are being referred to the Frauenspital, University of Berne will be asked to participate when admitted to the prenatal care unit because of risks for PTB, e.g. shortening of the cervical length, preterm contractions or prelabor premature rupture of membranes. We anticipate a 10% dropout rate. We intend to continuously match subjects in the control group to those in the risk groups. Consenting women will receive study examinations as well as obstetric standard of care during pregnancy provided by medical faculty investigators. Dental faculty investigators at the Department of Periodontology, University of Bern will perform dental examinations, data and sample collections from the participating subjects at either the Clinics of the Dental School or at the Frauenspital for bedridden pregnant women. There will be no specific dental interventions as part of the study. The dentists who normally provide care for study subjects will continue to do so. There are currently no known dental procedures that can reduce the risk for PTB. Dental procedures during pregnancy are considered at low or no risk to the pregnant women or the fetus. We will collect information on all medical and dental treatments performed during pregnancy. We will assess obstetric and dental clinical conditions, using procedures that we follow in both clinics. We will also assess bacteria and fungi in vaginal and oral compartments, and serum and local vaginal/oral inflammatory markers (cytokines and C-reactive protein). We recognize that genetic and socio-economic factors as well as ethnicity are important factors in risks for PTB. The control group will therefore be paired and matched for gestational age, ethnicity, age, parity and smoking. We anticipate that some of these subjects in the assigned no risk control group may actually deliver with PTB. Only women who deliver uneventfully will be included in the control group. |
||||||||
| Study Type ICMJE | Observational | ||||||||
| Study Design ICMJE | Observational Model: Case Control Time Perspective: Prospective |
||||||||
| Target Follow-Up Duration | Not Provided | ||||||||
| Biospecimen | Retention: Samples With DNA Description: Blood, vaginal smears, oral specimens |
||||||||
| Sampling Method | Non-Probability Sample | ||||||||
| Study Population | Pregnant women of more than 18 years of age. |
||||||||
| Condition ICMJE | Local or Systemic Signs for Infection, Preterm Birth | ||||||||
| Intervention ICMJE | Not Provided | ||||||||
| Study Group/Cohort (s) |
|
||||||||
| Publications * | Not Provided | ||||||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
| Recruitment Information | |||||||||
| Recruitment Status ICMJE | Recruiting | ||||||||
| Estimated Enrollment ICMJE | 180 | ||||||||
| Estimated Completion Date | December 2013 | ||||||||
| Estimated Primary Completion Date | December 2013 (final data collection date for primary outcome measure) | ||||||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||
| Gender | Female | ||||||||
| Ages | 18 Years and older | ||||||||
| Accepts Healthy Volunteers | Yes | ||||||||
| Contacts ICMJE |
|
||||||||
| Location Countries ICMJE | Switzerland | ||||||||
| Administrative Information | |||||||||
| NCT Number ICMJE | NCT01142752 | ||||||||
| Other Study ID Numbers ICMJE | KEK091/10 | ||||||||
| Has Data Monitoring Committee | Yes | ||||||||
| Responsible Party | Prof. Dr. D. V. Surbek, University women's hospital | ||||||||
| Study Sponsor ICMJE | University Hospital Inselspital, Berne | ||||||||
| Collaborators ICMJE | Not Provided | ||||||||
| Investigators ICMJE | Not Provided | ||||||||
| Information Provided By | University Hospital Inselspital, Berne | ||||||||
| Verification Date | December 2012 | ||||||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||||||